Navigation Links
Oxford BioMedica Announces Ocular Programme Update
Date:6/22/2011

plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs.  The Company's technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy.  Through in-house and collaborative research, Oxford BioMedica has a broad pipeline and its partners include Sanofi, Sigma-Aldrich and Pfizer.  Further information is available at http://www.oxfordbiomedica.co.uk.

2. Oxford BioMedica's agreement with Sanofi

Under the terms of the agreement signed with Sanofi in April 2009, Oxford BioMedica is responsible for the pre-clinical and initial Phase I/II studies of four lentiviral vector-based product candidates in the field of ophthalmology: RetinoStat® for "wet" AMD, StarGen™ for Stargardt disease, UshStat® for Usher syndrome 1B and EncorStat® for corneal graft rejection.  Oxford BioMedica granted Sanofi a license to develop the products and an option for further development, manufacture and commercialisation on a worldwide basis.  At any time prior to or within a defined period after completion of each Phase I/II study, Sanofi can exercise its option to license the products and will then assume responsibility for on-going activities.  Sanofi also has rights to broaden its license to develop the four products in additional indications, and has rights of first refusal to license other lentiviral vector-based products for the treatment of ocular diseases.

3. LentiVector® gene delivery technology

Oxford Bio
'/>"/>

SOURCE Oxford Biomedica Plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Oxford Finance Corporation Provides a $2 Million Equipment Facility to Synta Pharmaceuticals Corp.
2. Oxford BioTherapeutics Licenses BioWas POTELLIGENT® Technology for the Research and Development of its Therapeutic Antibodies in Cancer
3. ICAP Ocean Tomo Announces Four Patent Sets From Oxford Instruments - Each Represents an Important Advancement in Technology
4. Intuity Medical Secures $20M Credit Facility From Silicon Valley Bank and Oxford Finance Corporation
5. Oxford Finance Corporation Hires Debbie Baker to Support Life Science Business Development in Western North America
6. Oxford Finance Corporation Leads $30 Million Secured Loan Facility for Cadence Pharmaceuticals
7. Oxford Finance Corporation and United Orthopedic Group, Inc. Close $20 Million Credit Facility
8. Oxford Finance Corporation Facilitates Entry for Reata Pharmaceuticals into Asian Markets
9. Oxford Finance Corporation Closes $25 Million Credit Facility with EUSA Pharma
10. Oxford BioTherapeutics and GlaxoSmithKline Form Strategic Alliance to Develop Novel Cancer Therapeutic Antibodies
11. Saladax Biomedical, Inc. Completes $9 Million Debt Financing With GE Capital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 Oramed Pharmaceuticals Inc. ... pharmaceutical company focused on the development of oral ... results from its Phase IIa clinical trial of ... treat type 1 diabetes. The trial was conducted in ... a U.S. Food and Drug Administration (FDA) Investigational ...
(Date:10/22/2014)... Abaxis, Inc. (NasdaqGS: ABAX ), ... today reported financial results for the second fiscal quarter ... , Revenues of $53.9 million, up 18% over ... $0.24, up 33% over last year,s comparable quarter. ... Veterinary Reference Laboratories (AVRL) of $3.5 million, up 50% ...
(Date:10/22/2014)... -- InVivo Therapeutics Holdings Corp. (OTCQB: NVIV) based in ... cord injury (SCI) treatment with their novel Neuro-Spinal Scaffold. ... regrowth in the spinal cord area when cells are ... polymer, the scaffold ultimately breaks down to water and ... NVIV has recently attracted significant investor attention with the ...
Breaking Medicine Technology:Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 5Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 6Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 7Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 8Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 9Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 10Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 11Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 12Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 13Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 14InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 2InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 3
... Spinal Cord,Injury Model With ZFP TF Treatment, RICHMOND, ... announced today the presentation of preclinical,data from its ... Annual Conference of the American Society for Neural,Therapy ... of spinal cord,injury (SCI), demonstrate that treatment of ...
... 2007 /PRNewswire-FirstCall/ --,Citing issues related to potentially ... has concluded that the COSTAR,II (CObalt Chromium ... study for the CoStar cobalt chromium,paclitaxel-eluting coronary ... trial did not identify safety issues, and ...
Cached Medicine Technology:Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data,From Nerve Regeneration Program at American Society for Neural,Therapy and Repair Meeting 2Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data,From Nerve Regeneration Program at American Society for Neural,Therapy and Repair Meeting 3Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data,From Nerve Regeneration Program at American Society for Neural,Therapy and Repair Meeting 4Conor Medsystems, LLC Reports COSTAR II Pivotal Drug-Eluting Stent,Trial Conclusions 2Conor Medsystems, LLC Reports COSTAR II Pivotal Drug-Eluting Stent,Trial Conclusions 3Conor Medsystems, LLC Reports COSTAR II Pivotal Drug-Eluting Stent,Trial Conclusions 4
(Date:10/25/2014)... (HealthDay News) -- Interrupting blood supply to an arm or ... associated with the surgery, according to a new study. ... supply to the heart to be able to operate on ... reduce its ability to produce energy because it doesn,t get ... large muscle, such as an arm or a leg, the ...
(Date:10/25/2014)... THURSDAY, Oct. 23, 2014 (HealthDay News) -- A large ... West Africa is to avoid tens of thousands of ... Yale University researchers predict. Using a specially ... future of the outbreak in just one densely populated ... the capital city of Monrovia. The researchers said ...
(Date:10/22/2014)... Pennsylvania (PRWEB) October 22, 2014 At ... and uncertainty among parents and athletes at all levels, ... working to change the current discussion where two powerful ... are evidence-based therapies that result in full recoveries every ... to one based in fact and research, UPMC and ...
(Date:10/22/2014)... MI (PRWEB) October 22, 2014 ... Schools of Allied Health Professions (ASAHP) Conference on October ... and CEO will participate in a panel discussion on ... Practice. , Isabel Healthcare provides a diagnostic decision support ... improving the diagnosis skills of students and clinical learners. ...
(Date:10/22/2014)... 2014 Shriners Hospitals for Children® and ... the current location of Shriners Hospitals for Children - ... from the University of Kentucky Albert B. Chandler Hospital. ... center, owned and operated by Shriners Hospitals for Children, ... children and their families well into the future. , ...
Breaking Medicine News(10 mins):Health News:Brief Interruption of Blood Supply to Limb Might Aid Heart Surgery: Study 2Health News:Experts Predict 'Catastrophic' Ebola Epidemic in West Africa if Aid Delayed 2Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 2Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 3Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 4Health News:Isabel Healthcare to Participate in The Association of Schools of Allied Health Professions (ASAHP) 2014 Conference 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3
... centres will soon need to be registered and also adhere ... a new draft ‘Clinical Establishment Bill’ that has been finalised ... cabinet for approval. ,The proposed law will apply ... or Ayurvedic and the same parameters will apply to a ...
... scientists have successfully grown large numbers of stem cells taken ... to repair some of the tissue// damage done to those ... in humans, making them a useful model in such research. ... a thin tube to extract samples of heart tissue no ...
... proposes to link-up with tour operators to design tour ... and recreation in// the itinerary of tourists. ... secretary for Sports and Wellness of the Department of ... (Philippine Travel Agencies Association) and Naitas (The National Association ...
... Pharmaceutical Technology, Jadavpur University, Kolkata and Department of ... a// study on Plumeria Acuminata leaves. The objective ... anti-inflammatory activity of methanol extract of leaves of ... inflammation in rat hind paw oedema models. ...
... Science Award from Keio University in Tokyo. Mr. Steitz, ... received the award in a ceremony and commemorative symposium conducted ... award, made to researchers in recognition of their outstanding achievements ... only prize of its kind awarded by a Japanese University. ...
... who react slowly and possess bad memories are more prone ... ,Dr.Beverly Shipley, aged 28, from the Psychology dept., Edinburgh University ... heart attacks may be linked. She surveyed the mental agility ... all over Britain. ,She says that those with ...
Cached Medicine News:Health News:Pig Stem Cells Show Promise in Repairing Animals’ Heart Attack Damag 2Health News:Pig Stem Cells Show Promise in Repairing Animals’ Heart Attack Damag 3Health News:Anti Inflammatory Evaluation Of Plumeria Acuminata Leaves 2Health News:Yale Scientist Received Medical Science Prize From Keio University 2
... 2 O W/O Adapter., ... humidifier systems feature a dual-purpose reservoir with a ... secure attachment of a humidifier adapter. The oxygen ... reaching oxygen delivery tubing. An audible relief valve ...
... EMPTY W/AIR ENT 35%-100% FIO2, ,Empty ... 35% to 100%. It has ports for ... ,Empty Nebulizers 5007P and 5207 have ... , ,Convenient slip-on heaters are also ...
... , One device provides ... therapy from a single gas source ... decreasing the number of SKUs dedicated ... and inconvenience of double or wye ...
MISTY OX® Hi-Fi Nebulizer...
Medicine Products: